Brief: Novalgen To Begin World’s First Clinical Trial For A Self-Regulating Immunotherapy
17/09/2025 14:10
Sept 17 (Reuters) - Mabion SA MABP.WA: NOVALGEN TO BEGIN WORLD’S FIRST CLINICAL TRIAL FOR A SELF-REGULATING IMMUNOTHERAPY Source text: ID:nGNX5XfHbX Further company coverage: MABP.WA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects